LIVN — LivaNova PLC

Summary of LivaNova PLC Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $391 million, a 9.8% increase year-over-year on a constant currency basis.
• Cardiopulmonary Segment Revenue: $222 million, up 10% from Q2 2025, with strong growth in Europe.
• Epilepsy Segment Revenue: Increased 10%, with U.S. revenue up 8% and Europe/Rest of World up 15%.
• Adjusted Gross Margin: 71%, improved from 69% in Q2 2025, aided by a $6 million tariff refund.
• Adjusted Operating Income: $91 million, a 18% increase year-over-year.
• Adjusted Diluted EPS: $1.26, up from $1.05 in Q2 2025.
• Cash Position: $517 million, down from $636 million at year-end 2025; total debt reduced to $293 million.
• Adjusted Free Cash Flow: $46 million, slightly down from $48 million in the prior year.

2. Strategic Updates and Business Highlights

• Leadership Changes: New appointments include Stefano Folli as President of Cardiopulmonary and Anne Liddy as Chief Legal Officer.
• Thermo Fisher Partnership: A long-term agreement to secure critical components for oxygenators, enhancing manufacturing capacity and market share.
• Innovation Focus: Advancements in next-generation oxygenators and cloud-based clinician portals for epilepsy treatment.
• Market Share Gains: Cardiopulmonary market share in oxygenators increased from 30% to 40% over the past few years.

3. Forward Guidance and Outlook

• Cardiopulmonary Revenue Growth: Revised to 9.5% - 10.5% for 2026, up from 8.5% - 9.5%.
• Epilepsy Revenue Growth: Increased guidance to 7% - 8%, up from 6% - 7%.
• Overall Revenue Growth: Full-year 2026 guidance raised to 8% - 9%, up from 7% - 8%.
• Adjusted Diluted EPS Guidance: Projected in the range of $4.30 to $4.40 for 2026.
• Adjusted Free Cash Flow Guidance: Lowered to $140 million - $160 million from $160 million - $180 million due to increased capital expenditures.

4. Bad News, Challenges, or Points of Concern

• Cash and Debt Reduction: Cash decreased significantly, raising concerns about liquidity, although debt levels also fell.
• Tariff Refund: The $6 million tariff refund is a one-time benefit, which may not recur in future periods.
• U.S. Cardiopulmonary Growth: Some softness noted in U.S. growth, attributed to the maturation of the Essenz rollout and slower growth in certain consumables.
• Ongoing Competitive Pressures: The cannula market remains competitive, and recent recalls from competitors could impact market dynamics.

5. Notable Q&A Insights

• Thermo Fisher Partnership: The partnership is expected to alleviate supply constraints and enhance growth confidence in the Cardiopulmonary segment.
• Epilepsy Pricing Strategy: The company noted a significant increase in realized prices due to reduced volume discounting, which is expected to continue benefiting revenue.
• Ongoing Engagement with CMS: The company is actively engaging with CMS regarding reimbursement for VNS Therapy, with strong clinical data expected to support future discussions.
• Oxygenator Growth: Confidence remains high for continued growth in oxygenators, with new manufacturing capabilities expected to come online in 2027.

Overall, LivaNova reported a strong quarter with record revenues and EPS, driven by growth in both the Cardiopulmonary and Epilepsy segments, while also navigating challenges related to cash flow and competitive pressures.